Clover and Adimmune Enters into Exclusive Agreement to Commercialize AdimFlu-S (QIS) Influenza Vaccine in Mainland China
- Through this agreement, clover received commercial rights for the distribution of AdimFlu-S in mainland China. The NMPA approved it in Jan 2022 for individuals aged ≥3yrs. and expected to launch in H2’23
- Clover also has a second opportunity to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines on regulatory approvals, and to collaborate with Adimmune on the development of additional vaccine candidates
- AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine for influenza, it contains hemagglutinin from four influenza virus strains (two A and two B), due to which it has the potential to show high efficacy against seasonal influenza vaccine relative to trivalent options
Ref: GlobalNewswire | Image: Clover
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.